Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 6, 2012, Pages 791-802

  Kanakis, George ^a   Kaltsas, Gregory ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

5 HIAA; Carcinoid; Chromogranins; Gastrinoma; Glucagonoma; Insulinoma; Neuroendocrine tumours; Neuron Specific Enolase (NSE); Pancreatic polypeptide (PP); Somatostatinoma; VIPoma

Indexed keywords

CHORIONIC GONADOTROPIN; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; GLUCAGON; INSULIN; NEURON SPECIFIC ENOLASE; PANCREAS POLYPEPTIDE; PROINSULIN; SECRETOGRANIN II; SECRETOGRANIN III; SECRETOGRANIN IV; SECRETOGRANIN V; SECRETOGRANIN VI; SOMATOSTATIN; TUMOR MARKER; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOID SYNDROME; DISEASE MARKER; FOLLOW UP; GLUCAGONOMA; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; PANCREATIC NEUROENDOCRINE TUMOR; PARANEOPLASTIC SYNDROME; PREDICTION; SOMATOSTATINOMA; STOMACH ACID SECRETION; ZOLLINGER ELLISON SYNDROME;

EID: 84876103467     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.12.006     Document Type: Review

References (79)

1. G.A. Kaltsas, G.M. Besser, and A.B. Grossman The diagnosis and medical management of advanced neuroendocrine tumors Endocr Rev 25 3 2004 458 511
2. A. Vinik I.S. Institute, Editor Diagnosing and treating gastroenteropancreatic tumors, in neuroendocrine tumors: a comprehensive guide to diagnosis and management 2006 Inter Science Institute
3. G. Rindi, V. Villanacci, and A. Ubiali Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors Digestion 62 Suppl. 1 2000 19 26
4. K. Oberg Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours Endocr Relat Cancer 18 Suppl. 1 2011 S17 S25
5. W.W. de Herder, and K. Oberg I.O. Modlin, K. Oberg, Clinical and biochemical markers in a century of advances in neuroendocrine tumor biology and treatment 2007 Felsenstein CCCP
6. I.M. Modlin Gastroenteropancreatic neuroendocrine tumours Lancet Oncol 9 1 2008 61 72
7. E.S. Kilpatrick, and M.J. Lind Appropriate requesting of serum tumour markers BMJ 339 2009 b3111
8. B. Eriksson Chromogranins-new sensitive markers for neuroendocrine tumors Acta Oncol 28 3 1989 325 329
9. H. Winkler, and R. Fischer-Colbrie The chromogranins A and B: the first 25 years and future perspectives Neuroscience 49 3 1992 497 528
10. L. Taupenot, K.L. Harper, and D.T. O'Connor The chromogranin- secretogranin family N Engl J Med 348 12 2003 1134 1149
11. D.T. O'Connor Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism J Clin Endocrinol Metab 90 9 2005 5414 5425
12. D. O'Toole ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers Neuroendocrinology 90 2 2009 194 202
13. M. Stridsberg A comparison between three commercial kits for chromogranin A measurements J Endocrinol 177 2 2003 337 341
14. S. Welin Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors Neuroendocrinology 89 3 2009 302 307
15. K.I. Alexandraki, and G. Kaltsas Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy Endocrine 41 1 2012 40 52
16. D. Vezzosi Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study Int J Biol Markers 26 2 2011 94 101
17. R. Arnold Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors Clin Gastroenterol Hepatol 6 7 2008 820 827
18. B. Eriksson The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours Digestion 57 Suppl. 1 1996 77 80
19. S. Massironi Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors Am J Gastroenterol 105 9 2010 2072 2078
20. J.C. Yao Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus J Clin Endocrinol Metab 96 12 2011 3741 3749
21. R.L. Stronge A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours Ann Clin Biochem 45 Pt 6 2008 560 566
22. V. Marotta Limitations of chromogranin A in clinical practice Biomarkers 17 2 2012 186 191
23. D. O'Toole Current trend: endocrine tumors of the stomach, small bowel, colon and rectum Gastroenterol Clin Biol 30 2 2006 276 291
24. S. Sanduleanu Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy Eur J Clin Invest 31 9 2001 802 811
25. P. Ruszniewski Well-differentiated gastric tumors/carcinomas Neuroendocrinology 84 3 2006 158 164
26. R.J. Hsiao, M.S. Mezger, and D.T. O'Connor Chromogranin A in uremia: progressive retention of immunoreactive fragments Kidney Int 37 3 1990 955 964
27. D.J. Rozansky Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element J Clin Invest 94 6 1994 2357 2368
28. S.H. Yoo Localization of secretory granule marker protein chromogranin B in the nucleus Ann N Y Acad Sci 971 2002 345 348
29. N. Kimura Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors Mod Pathol 13 2 2000 140 146
30. G.M. Portela-Gomes Granins and granin-related peptides in neuroendocrine tumours Regul Pept 165 1 2010 12 20
31. M. Stridsberg A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B Regul Pept 125 1-3 2005 193 199
32. I.M. Modlin Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease Ann Surg Oncol 17 9 2010 2427 2443
33. F.R. Nobels Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones J Clin Endocrinol Metab 82 8 1997 2622 2628
34. F. Braga Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase Clin Biochem 46 1-2 2012 148 151
35. A. Franjevic, R. Pavicevic, and G. Bubanovic Differences in initial NSE levels in malignant and benign diseases of the thoracic wall Clin Lab 58 3-4 2012 245 252
36. C.M. Korse Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments Eur J Cancer 48 5 2012 662 671
37. E. Baudin Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours Br J Cancer 78 8 1998 1102 1107
38. J. Lonovics Pancreatic polypeptide. A review Arch Surg 116 10 1981 1256 1264
39. D.C. Metz, and R.T. Jensen Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors Gastroenterology 135 5 2008 1469 1492
40. M.A. Lewis, G.B. Thompson, and W.F. Young Jr. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1 World J Surg 36 6 2012 1375 1381
41. T. Tomita Pancreatic polypeptide in islet cell tumors. Morphologic and functional correlations Cancer 56 7 1985 1649 1657
42. T. Walter Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer 48 12 2012 1766 1773
43. T. Shah Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients Br J Cancer 99 1 2008 72 77
44. G. Kaltsas Paraneoplastic syndromes secondary to neuroendocrine tumours Endocr Relat Cancer 17 3 2010 R173 R193
45. M. Lesurtel Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives Cell Mol Life Sci 65 6 2008 940 952
46. I.P. Kema, E.G. de Vries, and F.A. Muskiet Measurement of 5-HIAA in urine Ann Clin Biochem 32 Pt 1 1995 102 104
47. W.G. Meijer Discriminating capacity of indole markers in the diagnosis of carcinoid tumors Clin Chem 46 10 2000 1588 1596
48. V. Formica The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract Br J Cancer 96 8 2007 1178 1182
49. A.J. Cleare A case of coeliac disease detected via raised 5-hydroxytryptamine and 5-hydroxyindoleacetic acid Ann Clin Biochem 34 Pt 4 1997 440 441
50. F. Mashige Acidic catecholamine metabolites and 5-hydroxyindoleacetic acid in urine: the influence of diet Ann Clin Biochem 33 Pt 1 1996 43 49
51. G.S. Sarna, P.H. Hutson, and G. Curzon Effect of alpha-methyl fluorodopa on dopamine metabolites: importance of conjugation and egress Eur J Pharmacol 100 3-4 1984 343 350
52. S. Bhattacharyya Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease Am J Cardiol 102 7 2008 938 942
53. F.J. Service Hypoglycemic disorders N Engl J Med 332 17 1995 1144 1152
54. B. Hirshberg Repaglinide-induced factitious hypoglycemia J Clin Endocrinol Metab 86 2 2001 475 477
55. P.C. Kao, R.L. Taylor, and F.J. Service Proinsulin by immunochemiluminometric assay for the diagnosis of insulinoma J Clin Endocrinol Metab 78 5 1994 1048 1051
56. F.J. Service, and N. Natt The prolonged fast J Clin Endocrinol Metab 85 11 2000 3973 3974
57. T.J. Merimee, and S.E. Fineberg Homeostasis during fasting. II. Hormone substrate differences between men and women J Clin Endocrinol Metab 37 5 1973 698 702
58. A.O. Hoff, and R. Vassilopoulou-Sellin The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia Cancer 82 8 1998 1585 1592
59. K. Iida Glucose-responsive insulinoma in a patient with postprandial hypoglycemia in the morning Intern Med 49 19 2010 2123 2127
60. M.J. Berna Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features Medicine (Baltim) 85 6 2006 331 364
61. H. Frucht Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study Ann Intern Med 111 9 1989 713 722
62. C. Shibata Criteria for the glucagon provocative test in the diagnosis of gastrinoma Surg Today 2012 Sep 16 [Epub ahead of print]
63. J.F. Rehfeld Pitfalls in diagnostic gastrin measurements Clin Chem 58 5 2012 831 836
64. D. O'Toole Rare functioning pancreatic endocrine tumors Neuroendocrinology 84 3 2006 189 195
65. A.I. Vinik Somatostatinomas, PPomas, neurotensinomas Semin Oncol 14 3 1987 263 281
66. J. Newell-Price Cushing's syndrome Lancet 367 9522 2006 1605 1617
67. R.A. DeLellis, and L. Xia Paraneoplastic endocrine syndromes: a review Endocr Pathol 14 4 2003 303 317
68. N.R. Biermasz Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients Pituitary 10 3 2007 237 249
69. G. Kanakis Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia J Clin Endocrinol Metab 97 4 2012 E627 E631
70. I.M. Modlin Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors Ann Surg Oncol 16 2 2009 487 498
71. J.L. Cunningham Tachykinins in endocrine tumors and the carcinoid syndrome Eur J Endocrinol 159 3 2008 275 282
72. M.C. Berkovic IL-2-330 T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs) J Mol Med (Berl) 88 4 2010 423 429
73. M.S. Khan Circulating tumor cells and EpCAM expression in neuroendocrine tumors Clin Cancer Res 17 2 2011 337 345
74. M. Cristofanilli Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 351 8 2004 781 791
75. J.S. de Bono Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 19 2008 6302 6309
76. T. Cui Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors PLoS One 5 12 2010 e16010
77. P.J. Lamy Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer Lung Cancer 29 3 2000 197 203
78. C.M. Korse An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival Ann Oncol 22 12 2011 2625 2630
79. I.M. Modlin A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival Neuroendocrinology 92 3 2010 143 157